nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Author index
|
|
|
2005 |
11 |
S2 |
p. 273-280 8 p. |
artikel |
2 |
Committees
|
|
|
2005 |
11 |
S2 |
p. viii-x nvt p. |
artikel |
3 |
ES159 A2 antagonists
|
|
|
2005 |
11 |
S2 |
p. 98- 1 p. |
artikel |
4 |
ES135 ADHD, Obsessive compulsive disorders & Tourette syndrome
|
|
|
2005 |
11 |
S2 |
p. 94- 1 p. |
artikel |
5 |
ES128 Antiglutamatergic compounds
|
|
|
2005 |
11 |
S2 |
p. 91- 1 p. |
artikel |
6 |
ES137 Antipsychotic treatment
|
|
|
2005 |
11 |
S2 |
p. 94- 1 p. |
artikel |
7 |
ES117 Atypical Parkinson's disease and tauopathies (PSP, CBDG, FTD-P)
|
|
|
2005 |
11 |
S2 |
p. 88-89 2 p. |
artikel |
8 |
ES130 Autonomic nervous system (vagaldysfunction)
|
|
|
2005 |
11 |
S2 |
p. 92- 1 p. |
artikel |
9 |
ES108 Basic aspects of tauopathies/synucleopathies
|
|
|
2005 |
11 |
S2 |
p. 86-87 2 p. |
artikel |
10 |
ES112 Biomarkers for the early diagnosis ofParkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 87- 1 p. |
artikel |
11 |
ES118 Cholinomimetics
|
|
|
2005 |
11 |
S2 |
p. 89- 1 p. |
artikel |
12 |
ES110 Clinimetry of cognition and behavior in Parkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 87- 1 p. |
artikel |
13 |
ES104 Deep brain stimulation (complications)
|
|
|
2005 |
11 |
S2 |
p. 85- 1 p. |
artikel |
14 |
ES145 Degenerative ataxias
|
|
|
2005 |
11 |
S2 |
p. 97- 1 p. |
artikel |
15 |
ES142 Drug study design
|
|
|
2005 |
11 |
S2 |
p. 96- 1 p. |
artikel |
16 |
ES113 Early onset Parkinsonism (Parkin,DJ-1 and PINK-1)
|
|
|
2005 |
11 |
S2 |
p. 88- 1 p. |
artikel |
17 |
ES120 Economics and disease related groups (DRG)
|
|
|
2005 |
11 |
S2 |
p. 89- 1 p. |
artikel |
18 |
ES121 Epidemiology
|
|
|
2005 |
11 |
S2 |
p. 90- 1 p. |
artikel |
19 |
ES133 Ethics
|
|
|
2005 |
11 |
S2 |
p. 93- 1 p. |
artikel |
20 |
ES143 Examination of specific cognitivedisturbances in Parkinson's disease patients
|
|
|
2005 |
11 |
S2 |
p. 96- 1 p. |
artikel |
21 |
ES131 Functional neuroanatomy
|
|
|
2005 |
11 |
S2 |
p. 92-93 2 p. |
artikel |
22 |
ES158 GAIT disorders
|
|
|
2005 |
11 |
S2 |
p. 97-98 2 p. |
artikel |
23 |
ES144 Gastrointestinal dysfunction inParkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 96- 1 p. |
artikel |
24 |
ES119 Gene therapy
|
|
|
2005 |
11 |
S2 |
p. 89- 1 p. |
artikel |
25 |
ES106 Genomics & proteomics (methodology)
|
|
|
2005 |
11 |
S2 |
p. 86- 1 p. |
artikel |
26 |
ES132 Haw to use the UPDRS and quality oflife scales
|
|
|
2005 |
11 |
S2 |
p. 93- 1 p. |
artikel |
27 |
ES157 How to cope with complications ofadvanced Parkinson's disease and algorithms approach
|
|
|
2005 |
11 |
S2 |
p. 97- 1 p. |
artikel |
28 |
ES123 Lewy body: Is it toxic orneuroprotective?
|
|
|
2005 |
11 |
S2 |
p. 90- 1 p. |
artikel |
29 |
ES107 Multiple system atrophy
|
|
|
2005 |
11 |
S2 |
p. 86- 1 p. |
artikel |
30 |
ES139 Natural compounds
|
|
|
2005 |
11 |
S2 |
p. 95- 1 p. |
artikel |
31 |
ES115 Neuroimaging (SPECT/MRI)
|
|
|
2005 |
11 |
S2 |
p. 88- 1 p. |
artikel |
32 |
ES125 Neuroimaging (SPECT, PET)
|
|
|
2005 |
11 |
S2 |
p. 90- 1 p. |
artikel |
33 |
ES156 Neurophysiological investigations in movement disorders
|
|
|
2005 |
11 |
S2 |
p. 97- 1 p. |
artikel |
34 |
ES124 Neurophysiology (EEG, ERP, MEG,TMS, direct current stimulation)
|
|
|
2005 |
11 |
S2 |
p. 90- 1 p. |
artikel |
35 |
ES138 (non) Motor response fluctuations
|
|
|
2005 |
11 |
S2 |
p. 95- 1 p. |
artikel |
36 |
ES127 Olfaction (basic aspects, clinics)
|
|
|
2005 |
11 |
S2 |
p. 91- 1 p. |
artikel |
37 |
ES101 Overview on current dopaminomimeticmedication
|
|
|
2005 |
11 |
S2 |
p. 84- 1 p. |
artikel |
38 |
ES102 Parkinson's disease related depression (treatment)
|
|
|
2005 |
11 |
S2 |
p. 84-85 2 p. |
artikel |
39 |
ES129 Psychological treatment (coping with the disease, sexual dysfunction and communication)
|
|
|
2005 |
11 |
S2 |
p. 91- 1 p. |
artikel |
40 |
ES126 Restless legs & RBD
|
|
|
2005 |
11 |
S2 |
p. 90-91 2 p. |
artikel |
41 |
ES134 Single neuroprotective drug or a cocktail?
|
|
|
2005 |
11 |
S2 |
p. 93- 1 p. |
artikel |
42 |
ES105 Sleep and Parkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 85- 1 p. |
artikel |
43 |
ES103 Stem cells (differentiation, (methodology)
|
|
|
2005 |
11 |
S2 |
p. 85- 1 p. |
artikel |
44 |
ES141 The effects of dance and live music on Parkinson's disease: Performance by Mark Morris Dance Group artists and pianist
|
|
|
2005 |
11 |
S2 |
p. 95-96 2 p. |
artikel |
45 |
ES136 Visual assessment (basic aspects,clinics)
|
|
|
2005 |
11 |
S2 |
p. 94- 1 p. |
artikel |
46 |
HT001 Hat topics: Treatment
|
|
|
2005 |
11 |
S2 |
p. 77- 1 p. |
artikel |
47 |
HT005 Hat topics: Treatment
|
|
|
2005 |
11 |
S2 |
p. 81-82 2 p. |
artikel |
48 |
HT002 Hot topics: Basal gangliapharmacology
|
|
|
2005 |
11 |
S2 |
p. 78- 1 p. |
artikel |
49 |
HT006 Hot topics: Genetics
|
|
|
2005 |
11 |
S2 |
p. 82-83 2 p. |
artikel |
50 |
HT004 Hot topics: STN Stimulation
|
|
|
2005 |
11 |
S2 |
p. 80- 1 p. |
artikel |
51 |
HT003 Hot topics: Varia
|
|
|
2005 |
11 |
S2 |
p. 78-79 2 p. |
artikel |
52 |
IS010 A novel botulinum toxin A product(Merz Pharma GmbH & Co. KGaA)
|
|
|
2005 |
11 |
S2 |
p. 266-268 3 p. |
artikel |
53 |
IS012 Continuous dopaminergic stimulation: New pharmacological approaches (NeuroBiotec GmbH/Axxonis Pharma)
|
|
|
2005 |
11 |
S2 |
p. 269-270 2 p. |
artikel |
54 |
IS011 Deep brain stimulation: the role of theneurologist for optimal patient benefits (Medtronic Inc.)
|
|
|
2005 |
11 |
S2 |
p. 268-269 2 p. |
artikel |
55 |
IS013 Dopamine agonists in clinical practice:Parkinson's disease treatment today and tomorrow (GlaxoSmithKline GmbH and Co KG)
|
|
|
2005 |
11 |
S2 |
p. 270- 1 p. |
artikel |
56 |
IS006 Dopamine transporter imaging — Challenging the evidence (GE Healthcare Ltd.)
|
|
|
2005 |
11 |
S2 |
p. 265- 1 p. |
artikel |
57 |
IS008 Exploring the role of adenosine A2Areceptors in the pathophysiology and treatment of Parkinson's disease (Kyowa Hakko Kogyo Co., LTD)
|
|
|
2005 |
11 |
S2 |
p. 266- 1 p. |
artikel |
58 |
IS001 Levodopa: the gold standard (NovartisPharma AG/Orion Corporation Orion Pharma)
|
|
|
2005 |
11 |
S2 |
p. 261- 1 p. |
artikel |
59 |
IS004 Rasagiline — A new and promising Parkinson's disease therapeutic approach (Lundbeck GmbH)
|
|
|
2005 |
11 |
S2 |
p. 263- 1 p. |
artikel |
60 |
IS005 Spheramine: A promisinginvestigational cell therapy far the treatment of Parkinson's disease (Schering AG/Titan Pharmaceuticals)
|
|
|
2005 |
11 |
S2 |
p. 264-265 2 p. |
artikel |
61 |
IS002 Subcutaneous apomorphine therapy inParkinson's disease — Recognising and overcoming the barriers (Britannia/Cephalon GmbH Germany)
|
|
|
2005 |
11 |
S2 |
p. 261-263 3 p. |
artikel |
62 |
IS003 The rotigotine patch: unique benefits forParkinsons disease patients (Schwarz Pharma AG)
|
|
|
2005 |
11 |
S2 |
p. 263- 1 p. |
artikel |
63 |
IS007 The scientific and clinical basisfar future therapies in Parlduson's disease (Boehringer Ingelheim GmbH & Co. KG)
|
|
|
2005 |
11 |
S2 |
p. 265-266 2 p. |
artikel |
64 |
IS009 Time to act: understanding restlesslegs syndrome (GlaxoSmithKline GmbH and Co KG)
|
|
|
2005 |
11 |
S2 |
p. 266- 1 p. |
artikel |
65 |
Medical historical exhibition
|
|
|
2005 |
11 |
S2 |
p. 271- 1 p. |
artikel |
66 |
[No title]
|
|
|
2005 |
11 |
S2 |
p. 100- 1 p. |
artikel |
67 |
[No title]
|
|
|
2005 |
11 |
S2 |
p. 101-102 2 p. |
artikel |
68 |
PL001 Pathophysiology
|
|
|
2005 |
11 |
S2 |
p. 53- 1 p. |
artikel |
69 |
PL003 Preclinical neuroprotection in Parkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 54-55 2 p. |
artikel |
70 |
PL002 Presidental plenary lecture
|
|
|
2005 |
11 |
S2 |
p. 53-54 2 p. |
artikel |
71 |
PL004 Treatment strategies
|
|
|
2005 |
11 |
S2 |
p. 55-57 3 p. |
artikel |
72 |
PS004 Botulinum toxin
|
|
|
2005 |
11 |
S2 |
p. 105-106 2 p. |
artikel |
73 |
PS003 Cannabis and cannabinoids in Parkinson's disease and movement disorder
|
|
|
2005 |
11 |
S2 |
p. 104-105 2 p. |
artikel |
74 |
PS002 Rotigotine
|
|
|
2005 |
11 |
S2 |
p. 103-104 2 p. |
artikel |
75 |
PT008 Animal models and Parkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 136-140 5 p. |
artikel |
76 |
PT022 Antidyskinetic drugs in animal models
|
|
|
2005 |
11 |
S2 |
p. 181-183 3 p. |
artikel |
77 |
PT014 Assessment of disease progression
|
|
|
2005 |
11 |
S2 |
p. 154-158 5 p. |
artikel |
78 |
PT032 Assessment of motor disturbances
|
|
|
2005 |
11 |
S2 |
p. 217-221 5 p. |
artikel |
79 |
PT044 Autonomic disturbances
|
|
|
2005 |
11 |
S2 |
p. 258-260 3 p. |
artikel |
80 |
PT002 Basic science: In vitro studies
|
|
|
2005 |
11 |
S2 |
p. 108-111 4 p. |
artikel |
81 |
PT015 Basic science: In viva studies
|
|
|
2005 |
11 |
S2 |
p. 158-161 4 p. |
artikel |
82 |
PT018 Cognitive disturbances
|
|
|
2005 |
11 |
S2 |
p. 169-173 5 p. |
artikel |
83 |
PT003 Deep brain stimulation I
|
|
|
2005 |
11 |
S2 |
p. 111-116 6 p. |
artikel |
84 |
PT027 Deep brain stimulation II
|
|
|
2005 |
11 |
S2 |
p. 195-200 6 p. |
artikel |
85 |
PT011 Depresion/sleep/pain
|
|
|
2005 |
11 |
S2 |
p. 144-147 4 p. |
artikel |
86 |
PT004 Dystonia and botulinum toxin
|
|
|
2005 |
11 |
S2 |
p. 116-122 7 p. |
artikel |
87 |
PT009 Economics
|
|
|
2005 |
11 |
S2 |
p. 140-142 3 p. |
artikel |
88 |
PT010 Etiopathogenesis
|
|
|
2005 |
11 |
S2 |
p. 142-144 3 p. |
artikel |
89 |
PT021 Etiopathogenesis - Environmental toxins
|
|
|
2005 |
11 |
S2 |
p. 178-180 3 p. |
artikel |
90 |
PT038 Etiopathogenesis — Metabolic disturbances
|
|
|
2005 |
11 |
S2 |
p. 235-238 4 p. |
artikel |
91 |
PT020 Experimental models — Cell cultures
|
|
|
2005 |
11 |
S2 |
p. 177-178 2 p. |
artikel |
92 |
PT025 Experimental models: Protein aggregation
|
|
|
2005 |
11 |
S2 |
p. 188-192 5 p. |
artikel |
93 |
PT030 Movement disorders
|
|
|
2005 |
11 |
S2 |
p. 210-214 5 p. |
artikel |
94 |
PT005 Movement disorders I
|
|
|
2005 |
11 |
S2 |
p. 122-126 5 p. |
artikel |
95 |
PT028 MSA and Ataxia
|
|
|
2005 |
11 |
S2 |
p. 201-205 5 p. |
artikel |
96 |
PT043 Neurogenetics
|
|
|
2005 |
11 |
S2 |
p. 254-258 5 p. |
artikel |
97 |
PT033 Neuroimaging 2 (MRI, TCS)
|
|
|
2005 |
11 |
S2 |
p. 221-224 4 p. |
artikel |
98 |
PT036 Neuroimaging 3 (PET)
|
|
|
2005 |
11 |
S2 |
p. 228-230 3 p. |
artikel |
99 |
PT013 Neuroimaging (SPECT)
|
|
|
2005 |
11 |
S2 |
p. 150-154 5 p. |
artikel |
100 |
PT001 Neuromelanin
|
|
|
2005 |
11 |
S2 |
p. 107-108 2 p. |
artikel |
101 |
PT040 Neurophysiology of movementdisorders
|
|
|
2005 |
11 |
S2 |
p. 242-247 6 p. |
artikel |
102 |
PT026 Neuroprotection in parkinsoniananimal models
|
|
|
2005 |
11 |
S2 |
p. 192-195 4 p. |
artikel |
103 |
PT037 Neurotoxin-induced movementdisorders
|
|
|
2005 |
11 |
S2 |
p. 230-235 6 p. |
artikel |
104 |
PT041 Non-pharmacological treatment of Parkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 247-250 4 p. |
artikel |
105 |
PT031 Pharmacological treatment: Dopamineagonists, Duo Dopa
|
|
|
2005 |
11 |
S2 |
p. 214-217 4 p. |
artikel |
106 |
PT007 Pharmacological treatment: Dopaminergics
|
|
|
2005 |
11 |
S2 |
p. 131-136 6 p. |
artikel |
107 |
PT006 Pharmacological treatment: MAO-S inhibitors, COMT-inhibitors
|
|
|
2005 |
11 |
S2 |
p. 126-131 6 p. |
artikel |
108 |
PT024 Pharmacological treatment: Varia
|
|
|
2005 |
11 |
S2 |
p. 185-187 3 p. |
artikel |
109 |
PT023 Phenotype and genetics: Park 1-2
|
|
|
2005 |
11 |
S2 |
p. 183-185 3 p. |
artikel |
110 |
PT042 Phenotype and genetics: Park 3–8
|
|
|
2005 |
11 |
S2 |
p. 250-254 5 p. |
artikel |
111 |
PT017 Postmortem studies
|
|
|
2005 |
11 |
S2 |
p. 165-169 5 p. |
artikel |
112 |
PT039 Preclinical pharmacology: in vitra
|
|
|
2005 |
11 |
S2 |
p. 239-242 4 p. |
artikel |
113 |
PT019 Preclinical pharmacology: In vivo
|
|
|
2005 |
11 |
S2 |
p. 173-176 4 p. |
artikel |
114 |
PT016 Quality of life
|
|
|
2005 |
11 |
S2 |
p. 161-165 5 p. |
artikel |
115 |
PT035 Transgenic models of movementdisorders
|
|
|
2005 |
11 |
S2 |
p. 226-228 3 p. |
artikel |
116 |
PT034 Treatment of non-motor symptoms
|
|
|
2005 |
11 |
S2 |
p. 224-226 3 p. |
artikel |
117 |
PT029 Tremor and restless legs syndrome
|
|
|
2005 |
11 |
S2 |
p. 205-210 6 p. |
artikel |
118 |
PT012 Wilson's disease
|
|
|
2005 |
11 |
S2 |
p. 147-149 3 p. |
artikel |
119 |
S013 Clinical aspects of neuroprotection
|
|
|
2005 |
11 |
S2 |
p. 70-71 2 p. |
artikel |
120 |
S014 Controversies on new animal models of Parkinson's disease: Pro and con
|
|
|
2005 |
11 |
S2 |
p. 71- 1 p. |
artikel |
121 |
S005 Development of midbrain dopaminergicneurons
|
|
|
2005 |
11 |
S2 |
p. 63-64 2 p. |
artikel |
122 |
S004 Dystonia
|
|
|
2005 |
11 |
S2 |
p. 62- 1 p. |
artikel |
123 |
S008 Functional neuroanatomy
|
|
|
2005 |
11 |
S2 |
p. 66-67 2 p. |
artikel |
124 |
S003 Melvin Yahr Memorial Symposium
|
|
|
2005 |
11 |
S2 |
p. 60-61 2 p. |
artikel |
125 |
S019 New pharmacological treatment - Latest trials
|
|
|
2005 |
11 |
S2 |
p. 75- 1 p. |
artikel |
126 |
S006 Non-motor manifestations
|
|
|
2005 |
11 |
S2 |
p. 64- 1 p. |
artikel |
127 |
S016 Non-motor manifestations and earlydiagnosis
|
|
|
2005 |
11 |
S2 |
p. 72-73 2 p. |
artikel |
128 |
S017 Parkinson-plus disorders: Diagnosis and treatment — State of the Art (SWEMODIS)
|
|
|
2005 |
11 |
S2 |
p. 73-74 2 p. |
artikel |
129 |
S007 Pathology, what's new?
|
|
|
2005 |
11 |
S2 |
p. 64-65 2 p. |
artikel |
130 |
S009 Pathophysiology — what's new
|
|
|
2005 |
11 |
S2 |
p. 67-68 2 p. |
artikel |
131 |
S010 Progress in familial Parkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 68- 1 p. |
artikel |
132 |
S012 Progress in PARK 8
|
|
|
2005 |
11 |
S2 |
p. 69-70 2 p. |
artikel |
133 |
S020 Role of P450 system in the CNS: implications for Parkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 75-76 2 p. |
artikel |
134 |
S018 Surgical interventions
|
|
|
2005 |
11 |
S2 |
p. 74-75 2 p. |
artikel |
135 |
S011 The role of iron in neurodegeneration
|
|
|
2005 |
11 |
S2 |
p. 68-69 2 p. |
artikel |
136 |
S001 The significance of neuromelanin in the human brain — Symposium 1: Structural and functional characterization of neuromelanin
|
|
|
2005 |
11 |
S2 |
p. 58-59 2 p. |
artikel |
137 |
S002 The significance of neuromelanin in the human brain — Symposium 2: The role of neuromelanin in the pathogenesis of Parkinson's disease
|
|
|
2005 |
11 |
S2 |
p. 59-60 2 p. |
artikel |
138 |
S015 Transcranial brain sonography inneurodegenerative diseases
|
|
|
2005 |
11 |
S2 |
p. 72- 1 p. |
artikel |
139 |
V148-1 Dystonia
|
|
|
2005 |
11 |
S2 |
p. 99- 1 p. |
artikel |
140 |
V148-2 Dystonia (repeat)
|
|
|
2005 |
11 |
S2 |
p. 99- 1 p. |
artikel |
141 |
V149-1 Psychogenic and psychiatric movement disorders
|
|
|
2005 |
11 |
S2 |
p. 99- 1 p. |
artikel |
142 |
V149-2 Psychogenic and psychiatric movement disorders (repeat)
|
|
|
2005 |
11 |
S2 |
p. 99- 1 p. |
artikel |
143 |
V147-1 Tics, chorea, myoclonus
|
|
|
2005 |
11 |
S2 |
p. 99- 1 p. |
artikel |
144 |
V147-2 Tics, chorea, myoclonus (repeat)
|
|
|
2005 |
11 |
S2 |
p. 99- 1 p. |
artikel |
145 |
V146-1 Tremor
|
|
|
2005 |
11 |
S2 |
p. 99- 1 p. |
artikel |
146 |
V146-2 Tremor (repeat)
|
|
|
2005 |
11 |
S2 |
p. 99- 1 p. |
artikel |
147 |
Welcome addresses
|
|
|
2005 |
11 |
S2 |
p. xi-xii nvt p. |
artikel |